Drugs / IMC-R117C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06840119 | Jan 2024 → Nov 2026 expected | cancer | Immunocore Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-01-05 | Immunocore Ltd | Regulatory Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation immunocore.com ↗
Submitted clinical trial applications (CTA) for IMC-R117C, a first-in-class ImmTAC targeting PIWIL1 for colorectal and other gastrointestinal cancers |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-R117C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06840119 ↗ |
| Modality | Protein / enzyme biologic | “IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein)” NCT06840119 ↗ |
| Route | Intravenous | “IV infusion” NCT06840119 ↗ |
| Target | PIWIL1 | “IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein)” NCT06840119 ↗ |